The trial’s primary efficacy endpoint is AF burden, which refers to the percentage of time a participant is in AF.

Acesion Pharma ("Acesion" or "the Company"), a biotech company pioneering treatments for atrial fibrillation ("AF"), the most common cardiac arrhythmia, today announces enrolment of the first patients ...

Please provide your email address to receive an email when new articles are posted on . Implantable loop recorder screening for atrial fibrillation did not significantly reduce the risk for stroke ...

MOUNTAIN VIEW, Calif., Nov. 12, 2018 /PRNewswire/ -- AliveCor, the leader in artificial intelligence and FDA-cleared personal electrocardiogram (ECG) technology, today announced new medical research ...

Please provide your email address to receive an email when new articles are posted on . Continuous implantable loop recorder monitoring resulted in a threefold increase in atrial fibrillation ...

Using an implantable loop recorder (ILR) to screen older individuals for atrial fibrillation (AF) may be more beneficial when NT-proBNP levels are high, according to a post hoc analysis of the LOOP ...

Atrial fibrillation was diagnosed in 477 of 1,501 (31.8%) participants in the monitoring group and 550 of 4,503 (12.2%) participants in the control group (HR 3.17, 95% CI 2.81-3.59, P<0.001), reported ...

Doctors at Columbus Community Hospital now have a high-tech new tool that can help them diagnose irregular heart rhythms that may not show up during standard testing. The tool, called a cardiac loop ...

Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.